May 16 |
Onconova Therapeutics GAAP EPS of -$0.24 beats by $0.01, revenue of $0.06M in-line
|
May 16 |
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 7 |
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
|
Apr 4 |
Traws Pharma Full Year 2023 Earnings: Beats Expectations
|
Apr 2 |
Onconova slips after all-stock merger with Trawsfynydd
|
Apr 2 |
Traws Pharma Announces New Employee Inducement Grants
|
Apr 2 |
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
|